Stronger and faster is not always better
December 10, 2019
Engineered T cells have been used to treat cancer, autoimmune diseases and infections. These cells are altered to express chimeric antigen receptors (CARs) that combine an antigen recognition domain with intracellular T cell signaling components which directs T cell specificity and functionality
Know More
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
December 02, 2019
When Jonathan Epstein first looked through the microscope to examine the results of a study using CAR T cells in mice, he didn’t know whether the sample came from a treated animal or a control
Know More
We participated into China Cell/Immuno Therapy Conference in Bejing
November 29, 2019
We participated into China Cell/Immuno Therapy Conference in Bejing on December 29-November 1, 2019. The pioneers in this field attended this event.
Know More
Cancer immunotherapy drug 'less toxic and prolongs life'
December 02, 2019
An immunotherapy drug that could save some cancer patients from the ordeal of extreme chemotherapy may also help them live longer, researchers say.
Know More
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
November 07, 2019
Refractory or relapsed B lymphoblastic leukemia (B-ALL) patients have a dismal outcome with current therapy. We treated 42 primary refractory/hematological relapsed (R/R) and 9 refractory minimal residual disease by flow cytometry (FCM-MRD + ) B-ALL
Know More
First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers
November 07, 2019
Cecilia Barron feels for one of the two bumps on her scalp. “Here it is,” she says, gently touching a spot on the top of her head. It’s invisible, unless Barron parts her hair to reveal the little nodule, a lump of flesh no bigger than a pea. In an hour, a nurse will come into the room, feel for the bumps, and slide a needle into each one, plunging millions of cells into Barron’s head
Know More
First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers
October 29, 2019
The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma
Know More
China Is Striving for the World’s Best, Cheapest Healthcare
Aug 10, 2019
Less than five years ago, Chinese healthcare was a closed-off, low-quality system where the richest left the country for medicines and treatments, and the poorest took a bad diagnosis as a death sentence.
Know More
Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance
Aug 02, 2019
In tumor cell immunity, T cells play a central regulatory role. T cells are divided into several major subsets based on different
Know More
CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial
Aug 02, 2019
A Chinese company has presented early clinical data on two CAR-T therapies in patients with kidney cancer
Know More
Clinical trials of CAR-T cells in China
Aug 02, 2019
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered
Know More
STEM Talent And China's Rise In The Race For CAR-T Immunotherapies
Aug 02, 2019
Timunity therapeutics is a biotech start-up company coming out of UPenn, with a cutting-edge technology in immunotherapy, it has recently attracted 135 million in funding for Series A. The start-up
Know More
China’s CAR-T Therapy Race
March 12, 2018
On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing
Know More
United States vs. China: The CAR T-Cell Therapy Landscape & Comparative Analysis
March 12, 2018
Researchers from the Office of Clinical Evaluation of Biological Products, Center for Drug Evaluation, China Food and Drug Administration recently produced
Know More
Patient In China Free Of Leukemia After CAR T Cell Therapy
March 24, 2019
In China, a patient whose life was close to its end was completely cured of leukemia by stimulating the immune system using CAR T-cell therapy
Know More
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
March 24, 2019
HANGZHOU, China, May 6, 2016 /PRNewswire/ -- At the 2016 Haematogenic Immunity Summit held in Hangzhou from April 22 to 24, 2016
Know More
CAR T Cells: Expanding into Multiple Myeloma
March 24, 2019
Before (left) and after (right) PET scans of a patient with multiple myeloma treated with BCMA-targeted CAR T cells.
Know More
CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update
March 24, 2019
Cellular therapies are a rapidly evolving approach to myeloma treatment, which bring a unique mechanism of action with the potential to overcome drug resistance and induce long-term remissions.
Know More
Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies
March 24, 2019
The burgeoning pipeline of chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA)
Know More
Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient | Blood Advances
March 24, 2019
Chimeric antigen receptor (CAR) gene therapy is a breakthrough technology in treating refractory hematologic malignancies
Know More
USC-led advance in groundbreaking cancer treatment eliminates severe side effects
March 24, 2019
an advance in the groundbreaking cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects
Know More
BCMA-Targeting CAR T-Cell Therapy Effective in R/R Myeloma?
March 24, 2019
A phase I study out of China has provided additional evidence that chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) leads to deep and durable responses in some patients
Know More
Joint New Zealand-China funding for CAR T-cell therapy research and development
May 21 2018
The Health Research Council (HRC) of New Zealand and the National Natural Science Foundation of China (NSFC) have announced a joint funding initiative to support further
Know More
CAR-T cell therapy saves cancer patients in China
May 21 2018
Instead of getting chemotherapy or waiting for hematopoietic stem cell transplantation, a 12-year-old girl from southwest China's Chongqing Municipality was saved by a non-conventional therapy
Know More
EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN CHILDREN WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKAEMIA
June 14 2018
Insights into CAR-T cell therapy presented at the 23rd Congress of the European Haematology Association, 14–17 June 2018, Stockholm
Know More
UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence
June 14 2018
LAKEWOOD, Colo., USA--October 9, 2018-- UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy
Know More
Present situation of China's CAR-T therapy
June 14 2018
Policy of CAR-T therapy in China 1.The declaration of CAR-T treatment in China has been accepted
Know More
J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial
June 14 2018
A Chinese CAR-T therapy that drew significant attention at last year’s American Society of Clinical Oncology meeting will enter a clinical trial in the US later this year.
Know More
Successful Clinical Results for a Novel CAR-T Cell Therapy: Is the Cure for Advanced Myeloma Patients within Our Reach
December 3, 2018
With regulatory approval of Chimeric Antigen Receptor (CAR) T-cell therapies for treating patients with aggressive blood cancer
Know More
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
16 July 2019
Division of Hematology, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium 2Laboratory of Experimental Hematology
Know More
Patient In China Free Of Leukemia After CAR T Cell Therapy
16 July 2019
In China, a patient whose life was close to its end was completely cured of leukemia by stimulating the immune system using CAR T-cell therapy
Know More
Anti-BCMA CAR T Cell Development Continues to Evolve for Multiple Myeloma
16 July 2019
Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile,
Know More
With some tweaks, CAR-T cancer therapy could be made safer — and more widely available — study suggests
16 July 2019
A novel approach to CAR-T cancer therapy promises to upend what has become a truism in medicine: that the treatment’s dramatic effect on tumors comes
Know More
The Latest Revolution in Cancer Treatment, Cell Therapy, is Moving Fast in China
July 29, 2018
The options available to cancer patients are changing rapidly thanks to developments in our understanding of the interplay between cancer and the immune system
Know More
CAR T Cells: Expanding into Multiple Myeloma
July 29, 2018
Results from two early-phase clinical trials suggest that a form of immunotherapy that uses genetically engineered immune cells may be highly effective
Know More